Dare Bioscience

Dare Bioscience Net Debt / EBITDA

The Net Debt to EBITDA of Dare Bioscience (DARE) as of Oct 31, 2026 is 1.63. In the previous year, Net Debt to EBITDA was 0.61 — a change of 165.13% (higher).

Net Debt / EBITDA

1.63

YoY

165.13%

Last updated:

Net Debt to EBITDA of Dare Bioscience is 2025 1.63 . Net Debt to EBITDA of Dare Bioscience was 2024 0.61 . It decreases by 165.13% higher compared to the previous year.

The Dare Bioscience Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
0.68 USD
Jan 1, 2019
0.28 USD
Jan 1, 2020
0.14 USD
Jan 1, 2021
1.32 USD
Jan 1, 2022
1.09 USD
Jan 1, 2023
0.29 USD
Jan 1, 2024
0.61 USD
Jan 1, 2025
1.63 USD
The Dare Bioscience Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
1.63+165.13%
0.61+109.35%
0.29-73.08%
1.09-17.23%
1.32+821.48%
0.14-48.53%
0.28-58.97%
0.68+13.53%
0.60-60.17%
1.50-36.89%
2.37+696.17%
0.30-73.57%
1.13-30.47%
1.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Net Debt to EBITDA of Dare Bioscience is 1.63 in 2025.

Net Debt to EBITDA of Dare Bioscience changed from 0.61 to 1.63, representing a 165.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Dare Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Dare Bioscience

All Key Metrics — Dare Bioscience